REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $57,928,676 | +75.0% | 568,151 | +56.0% | 0.17% | +67.0% |
| Q1 2023 | $33,103,972 | -27.2% | 364,100 | -79.9% | 0.10% | -43.4% |
| Q3 2022 | $45,502,000 | +676.2% | 1,810,647 | +2979.3% | 0.18% | +574.1% |
| Q1 2021 | $5,862,000 | +15.7% | 58,800 | +43.4% | 0.03% | +8.0% |
| Q4 2020 | $5,068,000 | -77.9% | 41,000 | -72.1% | 0.02% | -83.3% |
| Q2 2020 | $22,925,000 | -9.9% | 146,938 | -16.7% | 0.15% | -27.5% |
| Q1 2020 | $25,447,000 | -62.1% | 176,298 | -46.3% | 0.21% | -41.2% |
| Q4 2019 | $67,114,000 | +132.1% | 328,300 | -8.8% | 0.35% | +97.8% |
| Q3 2019 | $28,911,000 | -3.4% | 360,088 | +13.5% | 0.18% | +13.4% |
| Q2 2019 | $29,937,000 | +20.5% | 317,300 | +9.2% | 0.16% | +38.9% |
| Q1 2019 | $24,838,000 | +47.0% | 290,600 | -3.5% | 0.11% | +36.1% |
| Q4 2018 | $16,897,000 | -72.4% | 301,200 | -59.8% | 0.08% | -67.2% |
| Q3 2018 | $61,304,000 | +780.6% | 749,800 | +276.6% | 0.25% | +803.6% |
| Q2 2018 | $6,962,000 | – | 199,094 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |